Adicet Bio Inc (ACET)

$0.63 -0.05 (-6.71%)
Market Cap 51.74M
Revenue (ttm) 0.00
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 380,300
Avg Vol 504,312
Day's Range N/A - N/A
Shares Out 82.71M
Stochastic %K 1%
Beta 1.67
Analysts Strong Sell
Price Target $7.00

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 503 9095
Address:
131 Dartmouth Street, 3rd Floor, Boston, United States
Gator5326
Gator5326 Jun. 25 at 8:56 PM
$ACET Added 50% more. Tick tock 😎
0 · Reply
NYG4ever
NYG4ever Jun. 24 at 8:52 PM
$ACET Soon...very soon
2 · Reply
Gator5326
Gator5326 Jun. 18 at 11:46 AM
$ACET I own a nice piece of $ACET but may be adding to that stack today.
0 · Reply
Kevin_Gough
Kevin_Gough Jun. 18 at 10:26 AM
$ACET DT shows a 57.1M Market Cap and 131M Cash!!!
1 · Reply
NYG4ever
NYG4ever Jun. 16 at 4:07 PM
$ACET for those wondering - 40 - 50% of the daily volume is just short trading. No moves until news but if positive this will move past 1 in a hurry
0 · Reply
ralf2906
ralf2906 Jun. 16 at 3:59 PM
$ACET WTF is bringing this down?
1 · Reply
buymoremakemore
buymoremakemore Jun. 12 at 3:14 PM
$ACET 25,000 shares at $0.78 cost basis. I like what I see in terms of tutes and cash and several well known investors in the field are bullish.
0 · Reply
OnTheFringe
OnTheFringe Jun. 11 at 11:28 AM
$ACET I can feel it, can you?
1 · Reply
OnTheFringe
OnTheFringe Jun. 10 at 9:55 PM
$ACET nice move at the close and a break above the resistance.
0 · Reply
UnicornChaser
UnicornChaser Jun. 10 at 8:20 PM
$ACET here we go📈📈📈💪💪💪
0 · Reply
Latest News on ACET
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:00 PM EDT - 5 weeks ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:01 PM EDT - 7 weeks ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2025, 4:47 PM EDT - 2 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 2 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Apr 17, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 5:12 PM EDT - 3 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 4:01 PM EST - 4 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Mar 3, 2025, 7:00 AM EST - 4 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 27, 2025, 7:00 AM EST - 4 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Feb 5, 2025, 7:10 AM EST - 5 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:00 AM EST - 5 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Jan 8, 2025, 4:10 PM EST - 6 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2024, 4:48 PM EST - 6 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 19, 2024, 7:00 AM EST - 6 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dec 18, 2024, 7:00 AM EST - 6 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 4:00 PM EST - 7 months ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 18, 2024, 7:00 AM EST - 7 months ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 16, 2024, 9:00 AM EST - 8 months ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:00 PM EST - 8 months ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 5, 2024, 7:00 AM EST - 8 months ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 8 months ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Oct 16, 2024, 7:00 AM EDT - 9 months ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 4:30 PM EDT - 9 months ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 30, 2024, 7:00 AM EDT - 9 months ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 19, 2024, 7:00 AM EDT - 10 months ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 4:00 PM EDT - 10 months ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 19, 2024, 7:00 AM EDT - 11 months ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 11 months ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jan 25, 2024, 4:01 PM EST - 1 year ago

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Pricing of Public Offering

Jan 22, 2024, 11:43 PM EST - 1 year ago

Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering

Jan 22, 2024, 4:28 PM EST - 1 year ago

Adicet Bio, Inc. Announces Proposed Public Offering

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Jan 8, 2024, 7:19 PM EST - 1 year ago

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Jan 3, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 10, 2023, 12:00 PM EST - 1 year ago

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 4:10 PM EST - 1 year ago

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Gator5326
Gator5326 Jun. 25 at 8:56 PM
$ACET Added 50% more. Tick tock 😎
0 · Reply
NYG4ever
NYG4ever Jun. 24 at 8:52 PM
$ACET Soon...very soon
2 · Reply
Gator5326
Gator5326 Jun. 18 at 11:46 AM
$ACET I own a nice piece of $ACET but may be adding to that stack today.
0 · Reply
Kevin_Gough
Kevin_Gough Jun. 18 at 10:26 AM
$ACET DT shows a 57.1M Market Cap and 131M Cash!!!
1 · Reply
NYG4ever
NYG4ever Jun. 16 at 4:07 PM
$ACET for those wondering - 40 - 50% of the daily volume is just short trading. No moves until news but if positive this will move past 1 in a hurry
0 · Reply
ralf2906
ralf2906 Jun. 16 at 3:59 PM
$ACET WTF is bringing this down?
1 · Reply
buymoremakemore
buymoremakemore Jun. 12 at 3:14 PM
$ACET 25,000 shares at $0.78 cost basis. I like what I see in terms of tutes and cash and several well known investors in the field are bullish.
0 · Reply
OnTheFringe
OnTheFringe Jun. 11 at 11:28 AM
$ACET I can feel it, can you?
1 · Reply
OnTheFringe
OnTheFringe Jun. 10 at 9:55 PM
$ACET nice move at the close and a break above the resistance.
0 · Reply
UnicornChaser
UnicornChaser Jun. 10 at 8:20 PM
$ACET here we go📈📈📈💪💪💪
0 · Reply
Kevin_Gough
Kevin_Gough Jun. 10 at 7:59 PM
$ACET Well it is about time!!!
0 · Reply
Zgod
Zgod Jun. 10 at 6:44 AM
$ACET feeling good about $1 coming soon
0 · Reply
UnicornChaser
UnicornChaser Jun. 6 at 1:53 PM
$ACET daily has been pushing. Need to break past .80c and we’ll be headed towards $1.00 🔥
0 · Reply
OnTheFringe
OnTheFringe Jun. 6 at 1:40 PM
$ACET Watched the webcast of last presentation and you should too.
1 · Reply
OnTheFringe
OnTheFringe Jun. 6 at 12:54 PM
$ACET so we found some resistance, all we need is dosing results.
0 · Reply
OnTheFringe
OnTheFringe Jun. 5 at 1:02 PM
$ACET close above .85 with a green hammer?
0 · Reply
sam92
sam92 Jun. 4 at 8:19 PM
$ACET Should hit the bullish volume scanners in the AM the morning after the Jefferies Global Healthcare Conference 2025
1 · Reply
UnicornChaser
UnicornChaser Jun. 4 at 5:42 PM
$ACET close to breaking into 0.80’s 😎😎😎
1 · Reply
trader348
trader348 Jun. 4 at 4:03 PM
$ACET Por que no se puede vender esta accion alguien sabe si la sacaon de la bolsa
0 · Reply
UnicornChaser
UnicornChaser Jun. 3 at 11:51 PM
$ACET continues to trend up. Slow and steady ⬆️⬆️⬆️⬆️⬆️
0 · Reply
AGC_Trader
AGC_Trader Jun. 2 at 2:15 PM
$ACET $0.72 seems to be a big resistance
2 · Reply
OnTheFringe
OnTheFringe Jun. 2 at 1:09 PM
$ACET Why did Gordon who leads Orbimed's private equity investment team leave the board of ACET?
0 · Reply